STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial

Eli Lilly reported Thursday that in a late-stage trial, its next-generation obesity drug led to levels of weight loss approaching the effectiveness seen with bariatric surgery, but that there were high rates of side effects and discontinuations, raising questions about how appealing the treatment would be.  In the Phase 3 study, which enrolled obese and overweight people who didn’t have diabetes, those who took the highest dose and stayed on the treatment, called retatrutide, lost on average 28....